Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
ATLANTA, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be...
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Portugal
Reimbursement granted with no restrictions to the labelAlimera to begin selling later in Q3 ATLANTA, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences,...
Alimera Sciences Announces Second Quarter 2022 Financial Results
Consolidated Net Product Revenue of $14.6 Million up 36% vs. Second Quarter of 2021U.S. End User Demand up 45% vs. Second Quarter of 2021International...